These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35849476)

  • 21. Short-term administration of oral relugolix before single-port laparoscopic-assisted vaginal hysterectomy for symptomatic uterine myomas: A retrospective comparative study with leuprorelin injection.
    Takeda A
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1921-1929. PubMed ID: 35460303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
    Arjona Ferreira JC; Migoya E
    F S Rep; 2023 Jun; 4(2 Suppl):73-82. PubMed ID: 37223761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis.
    Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Dynowski K; Wilk K; Li Y; Mathur V; Wagman RB; Johnson NP
    Pain Manag; 2023 Nov; 13(11):631-640. PubMed ID: 37982388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
    Ali M; Chen HY; Chiang YF; Badary OA; Hsia SM; Al-Hendy A
    Expert Opin Pharmacother; 2022 Mar; 23(4):421-429. PubMed ID: 35068291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
    Blair HA
    Drugs; 2024 Apr; 84(4):449-457. PubMed ID: 38592603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relugolix and elagolix directly inhibit leiomyoma extracellular matrix production in 2-dimesnional and 3-dimensional cell cultures.
    Wright D; Britten J; Malik M; Catherino WH
    F S Sci; 2022 Aug; 3(3):299-308. PubMed ID: 35977805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
    Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
    Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Brown E; Dynowski K; Wilk K; Li Y; Mathur V; Warsi QA; Wagman RB; Johnson NP
    Lancet; 2022 Jun; 399(10343):2267-2279. PubMed ID: 35717987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain.
    As-Sanie S; Abrao MS; Reznichenko G; Wilk K; Zhong Y; Perry J; Hunsche E; Soulban G; Becker CM
    Fertil Steril; 2024 Jun; ():. PubMed ID: 38906210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relugolix for the treatment of uterine fibroids.
    Rocca ML; Palumbo AR; Lico D; Fiorenza A; Bitonti G; D'Agostino S; Gallo C; Di Carlo C; Zullo F; Venturella R
    Expert Opin Pharmacother; 2020 Oct; 21(14):1667-1674. PubMed ID: 32674616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relugolix combination therapy and symptoms of uterine myomatosis - selected case reports of indication spectrum and treatment outcomes.
    Hudeček R; Klát J; Pohl K; Prokopenko A; Mikulášek L; Šimová S; Krčál P; Ševčík A; Tomeš P
    Ceska Gynekol; 2023; 88(5):359-370. PubMed ID: 37932053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy).
    Venable SR; Al-Hendy A
    Adv Ther; 2023 Oct; 40(10):4127-4133. PubMed ID: 37568061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of GnRH Antagonists as Treatment for Abnormal Uterine Bleeding-Leiomyoma (AUB-L) and Their Influence on the Readiness of Service Members.
    Wright D; Kim JW; Lindsay H; Catherino WH
    Mil Med; 2022 Mar; ():. PubMed ID: 35348746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial.
    Alkhrait S; Al-Hendy A; Alkelani H; Karrison T; Laveaux OSM
    PLoS One; 2024; 19(7):e0306053. PubMed ID: 38954680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relugolix: First Global Approval.
    Markham A
    Drugs; 2019 Apr; 79(6):675-679. PubMed ID: 30937733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relugolix for the treatment of uterine fibroids.
    Barra F; Seca M; Della Corte L; Giampaolino P; Ferrero S
    Drugs Today (Barc); 2019 Aug; 55(8):503-512. PubMed ID: 31461087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
    Neblett MF; Stewart EA
    Obstet Gynecol; 2023 May; 141(5):901-910. PubMed ID: 37103532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix.
    Yamanaka K; Washio K; Uchida A; Sasagawa Y; Nishimoto M; Yamasaki Y; Nagamata S; Terai Y
    Gynecol Endocrinol; 2023 Dec; 39(1):2237121. PubMed ID: 37537884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Oral GnRh Antagonists in Patients With Uterine Fibroids: A Systematic Review.
    Niaz R; Saeed M; Khan H; Ali MA; Irshad A; Faiz M; Irshad A; Fatima F; Tunio SA; Aiman W
    J Obstet Gynaecol Can; 2022 Dec; 44(12):1279-1288. PubMed ID: 36368594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
    Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
    Fertil Steril; 2021 Feb; 115(2):397-405. PubMed ID: 32912633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.